Country: Canada
Language: English
Source: Health Canada
TOPIRAMATE
ANGITA PHARMA INC.
N03AX11
TOPIRAMATE
100MG
TABLET
TOPIRAMATE 100MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0132938002; AHFS:
APPROVED
2023-03-30
_ _ _AG-Topiramate Tablets_ _Page 1 of 73_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AG-TOPIRAMATE TABLETS Topiramate Tablets Tablets, 25 mg, 100 mg and 200 mg, oral USP Antiepileptic/Migraine Prophylaxis Angita Pharma Inc. 1310 Nobel Street Boucherville, Québec J4B 5H3 Date of Initial Authorization: MAR 30, 2023 Submission Control Number: 272943 _ _ _AG-Topiramate Tablets_ _Page 2 of 73_ RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS _Sections or subsections that are not applicable at the time of authorization are not listed._ RECENT MAJOR LABEL CHANGES ............................................................................................... 2 TABLE OF CONTENTS ..................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics .................................................................................................................. 4 1.2 Geriatrics ............................................................................................................. 4 2 CONTRAINDICATIONS ..................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations ................................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment ........................................................ 5 4.4 Administration ........................................................................................................... 7 4.5 Missed Dose ................................................................................................................. 7 5 OVE Read the complete document